Imunon, Inc. reports developments as a clinical-stage biotechnology company advancing non-viral DNA technologies for immunotherapy and vaccines. Its lead candidate, IMNN-001, is a DNA-based interleukin-12 immunotherapy being developed for localized treatment of newly diagnosed advanced ovarian cancer through the OVATION clinical program.
Company news commonly covers clinical data from OVATION studies, Phase 3 development activity, financial results and business updates, and portfolio work around the TheraPlas platform for cytokine and therapeutic-protein delivery and the PlaCCine platform for viral-antigen delivery. Updates also include capital discipline, organization changes, and presentations of translational or proof-of-concept data.
Imunon, Inc. (NASDAQ: IMNN) reports promising partial results from a non-human primate study evaluating its PLACCINE vaccine as a potential alternative to mRNA vaccines. In the study, Cynomolgus monkeys showed comparable immunogenicity and viral clearance after vaccination with PLACCINE and a commercial mRNA vaccine. The PLACCINE technology, which uses a synthetic DNA delivery system, demonstrated stability and potential safety advantages. The study underlines the capability of PLACCINE to target viral mutations and enhances efficacy through potent immune modifiers.
Imunon, Inc. (NASDAQ: IMNN) announced that its Compensation Committee approved the grant of inducement stock options and restricted stock grants to two new hires during Q3 2022. The stock options allow purchasing 8,500 shares at an exercise price of $1.65, equal to its closing stock price on September 27, 2022. Vesting occurs in thirds over three years, fully exercisable by September 2025. The restricted stock grants total 2,250 shares, vesting on the one-year anniversary of each employee's start date.
Imunon (NASDAQ: IMNN) announced CEO Dr. Corinne Le Goff will present at the Chardan 6th Annual Genetic Medicines Conference on October 3-4, 2022, in New York City. Dr. Le Goff's presentation is scheduled for October 3 at 2:30 PM ET, and it will be available live and on-demand. Imunon is a clinical-stage biotechnology company developing innovative treatments using its two platforms: TheraPlas for immunotherapies and PLACCINE for nucleic acid vaccines. The company is focused on addressing advanced ovarian cancer with its lead program, GEN-1.